Although a statistically significant difference between the expression of ZC3H12D and the survival of HER2+ breast cancer patients was not observed, a similar trend indicated that breast cancer patients with low ZC3H12D expression experienced shorter survival (Figure 1H). Here, ERBB2 is linked to breast carcinoma.